Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00119392 · OUTCOME

Treatment Related Mortality (TRM)

Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · Source last updated 2018-06-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percent
Interval / dispersion
95% Confidence Interval
Time frame
At day +100

What was measured

Cumulative incidence rate of treatment related mortality with relapse as a competing risk, assessed at 30 months.

Groups in this outcome

Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)

See Detailed Description rituximab: Given IV cyclosporine: Given orally fludarabine phosphate: Given IV mycophenolate mofetil: Given orally yttrium Y 90 ibritumomab tiuxetan: Given IV peripheral blood stem cell transplantation: Undergo transplantation allogeneic hematopoietic stem cell transplantation: Undergo transplantation total-body irradiation: Undergo TBI

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)40

Reported measurements

Source class 1
Values in percent · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)16Not reported428Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        4
        upper Limit
        28
        value
        16
denoms
  1. counts
    1. group Id
      OG000
      value
      40
    units
    Participants
description
Cumulative incidence rate of treatment related mortality with relapse as a competing risk, assessed at 30 months.
dispersion Type
95% Confidence Interval
groups
  1. description
    See Detailed Description rituximab: Given IV cyclosporine: Given orally fludarabine phosphate: Given IV mycophenolate mofetil: Given orally yttrium Y 90 ibritumomab tiuxetan: Given IV peripheral blood stem cell transplantation: Undergo transplantation allogeneic hematopoietic stem cell transplantation: Undergo transplantation total-body irradiation: Undergo TBI
    id
    OG000
    title
    Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)
param Type
NUMBER
reporting Status
POSTED
time Frame
At day +100
title
Treatment Related Mortality (TRM)
type
PRIMARY
unit Of Measure
percent

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice